A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 36(2022), 2 vom: 30. Feb., Seite e111-e113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hansel, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
90ZX3Q3FR7 |
|---|
| Anmerkungen: |
Date Completed 20.01.2022 Date Revised 20.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.17656 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330527614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330527614 | ||
| 003 | DE-627 | ||
| 005 | 20231225211458.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.17656 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330527614 | ||
| 035 | |a (NLM)34510556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hansel, K |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2022 | ||
| 500 | |a Date Revised 20.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a risankizumab |2 NLM | |
| 650 | 7 | |a 90ZX3Q3FR7 |2 NLM | |
| 700 | 1 | |a Zangrilli, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 700 | 1 | |a Chiricozzi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Offidani, A |e verfasserin |4 aut | |
| 700 | 1 | |a Diotallevi, F |e verfasserin |4 aut | |
| 700 | 1 | |a Fargnoli, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, M |e verfasserin |4 aut | |
| 700 | 1 | |a Amerio, P |e verfasserin |4 aut | |
| 700 | 1 | |a Gualdi, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Stingeni, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 36(2022), 2 vom: 30. Feb., Seite e111-e113 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:2 |g day:30 |g month:02 |g pages:e111-e113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.17656 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 2 |b 30 |c 02 |h e111-e113 | ||